11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Cosentyx

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
C C
C C

Sekukinumab

Sekukinumab

Klass : C

Visa all info

Skriv ut

Kontakta oss

  1. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.

  2. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.

  3. Lee JE, Wang J, Florian J, Wang YM, Kettl D, Marcus K et al. Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis. Clin Pharmacol Ther. 2019;106(1):78-80.

  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - COSENTYX (secukinumab). Drugs@FDA [www]. [updated 2015-02-19, cited 2022-10-17].

  5. Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021;23(1):231.

  6. García-Dorta A, León-Suarez P, Peña S, Hernández-Díaz M, Rodríguez-Lozano C, González-Dávila E et al. Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study. Front Med (Lausanne). 2021;8:815881.

  7. Alonso S, Villa I, Fernández S, Martín JL, Charca L, Pino M et al. Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med (Lausanne). 2021;8:679009.

  8. Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7(1):.

  9. Geale K, Lindberg I, Paulsson EC, Wennerström ECM, Tjärnlund A, Noel W et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.

  10. Torres T, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P et al. Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273-275.

  11. Daudén E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, Villarasa E et al. Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain. Dermatol Ther (Heidelb). 2021;11(6):2207-2215.

  12. Kojanova M, Hugo J, Velackova B, Cetkovska P, Fialova J, Dolezal T et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022;33(6):2827-2837.

  13. Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM et al. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. Am J Clin Dermatol. 2021;22(4):567-579.

  14. Oh S, Choi S, Yoon HS. Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis. Ann Dermatol. 2022;34(5):321-330.

  15. van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913-1920.

  16. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]

  1. Exarchou S, Lindström U, Askling J, Eriksson JK, Forsblad-d'Elia H, Neovius M et al. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015;17(1):118.
  2. Löfvendahl S, Theander E, Svensson Å, Carlsson KS, Englund M, Petersson IF. Validity of diagnostic codes and prevalence of physician-diagnosed psoriasis and psoriatic arthritis in southern Sweden--a population-based register study. PLoS One. 2014;9(5):e98024.
  3. Lee JE, Wang J, Florian J, Wang YM, Kettl D, Marcus K et al. Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis. Clin Pharmacol Ther. 2019;106(1):78-80.
  4. Food and Drug Administration (FDA). Clinical Pharmacology and Biopharmaceutics Review - COSENTYX (secukinumab). Drugs@FDA [www]. [updated 2015-02-19, cited 2022-10-17].
  5. Braun J, Blanco R, Marzo-Ortega H, Gensler LS, van den Bosch F, Hall S et al. Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT. Arthritis Res Ther. 2021;23(1):231.
  6. García-Dorta A, León-Suarez P, Peña S, Hernández-Díaz M, Rodríguez-Lozano C, González-Dávila E et al. Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study. Front Med (Lausanne). 2021;8:815881.
  7. Alonso S, Villa I, Fernández S, Martín JL, Charca L, Pino M et al. Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Front Med (Lausanne). 2021;8:679009.
  8. Ramonda R, Lorenzin M, Carriero A, Chimenti MS, Scarpa R, Marchesoni A et al. Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open. 2021;7(1):.
  9. Geale K, Lindberg I, Paulsson EC, Wennerström ECM, Tjärnlund A, Noel W et al. Persistence of biologic treatments in psoriatic arthritis: a population-based study in Sweden. Rheumatol Adv Pract. 2020;4(2):rkaa070.
  10. Torres T, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P et al. Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study. J Am Acad Dermatol. 2019;81(1):273-275.
  11. Daudén E, de Lima GPG, Armesto S, Herrera-Acosta E, Vidal D, Villarasa E et al. Multicenter Retrospective Study of Secukinumab Drug Survival in Psoriasis Patients in a Daily Practice Setting: A Long-Term Experience in Spain. Dermatol Ther (Heidelb). 2021;11(6):2207-2215.
  12. Kojanova M, Hugo J, Velackova B, Cetkovska P, Fialova J, Dolezal T et al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022;33(6):2827-2837.
  13. Torres T, Puig L, Vender R, Lynde C, Piaserico S, Carrascosa JM et al. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. Am J Clin Dermatol. 2021;22(4):567-579.
  14. Oh S, Choi S, Yoon HS. Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis. Ann Dermatol. 2022;34(5):321-330.
  15. van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913-1920.
  16. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2021 [cited 2022-03-15.]